MA38341A1 - Modulateurs d'enzymes de modification par méthylation, compositions et utilisations associées - Google Patents
Modulateurs d'enzymes de modification par méthylation, compositions et utilisations associéesInfo
- Publication number
- MA38341A1 MA38341A1 MA38341A MA38341A MA38341A1 MA 38341 A1 MA38341 A1 MA 38341A1 MA 38341 A MA38341 A MA 38341A MA 38341 A MA38341 A MA 38341A MA 38341 A1 MA38341 A1 MA 38341A1
- Authority
- MA
- Morocco
- Prior art keywords
- compositions
- methylation modification
- modification enzyme
- enzyme modulators
- modulators
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Epidemiology (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
Abstract
L'invention concerne des agents ayant la formule structurelle (ii) pour moduler des enzymes de modification par méthylation des histones, des compositions et des utilisations de ceux-ci, par exemple, en tant qu'agents anticancéreux.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US2013/025639 WO2013120104A2 (fr) | 2012-02-10 | 2013-02-11 | Modulateurs d'enzymes de modification par méthylation, leurs compositions et utilisations |
PCT/US2014/015706 WO2014124418A1 (fr) | 2013-02-11 | 2014-02-11 | Modulateurs d'enzymes de modification par méthylation, compositions et utilisations associées |
Publications (2)
Publication Number | Publication Date |
---|---|
MA38341A1 true MA38341A1 (fr) | 2018-01-31 |
MA38341B1 MA38341B1 (fr) | 2018-11-30 |
Family
ID=50239937
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA38341A MA38341B1 (fr) | 2013-02-11 | 2014-02-11 | Modulateurs d'enzymes de modification par méthylation, compositions et utilisations associées |
Country Status (17)
Country | Link |
---|---|
EP (1) | EP2953941B1 (fr) |
KR (1) | KR102219441B1 (fr) |
CN (1) | CN105102446B (fr) |
CL (1) | CL2015002239A1 (fr) |
CR (1) | CR20150457A (fr) |
HK (1) | HK1218648A1 (fr) |
IL (1) | IL239985B (fr) |
MA (1) | MA38341B1 (fr) |
ME (1) | ME02730B (fr) |
PE (1) | PE20160044A1 (fr) |
PH (1) | PH12015501720A1 (fr) |
PL (1) | PL2953941T3 (fr) |
RS (1) | RS56207B1 (fr) |
SG (1) | SG11201506077XA (fr) |
SI (1) | SI2953941T1 (fr) |
TW (1) | TWI629273B (fr) |
WO (1) | WO2014124418A1 (fr) |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130102477A1 (en) | 2010-06-23 | 2013-04-25 | Ryan D. Morin | Biomarkers for non-hodgkin lymphomas and uses thereof |
US9051269B2 (en) | 2011-11-18 | 2015-06-09 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
WO2013120104A2 (fr) | 2012-02-10 | 2013-08-15 | Constellation Pharmaceuticals | Modulateurs d'enzymes de modification par méthylation, leurs compositions et utilisations |
WO2015023915A1 (fr) * | 2013-08-15 | 2015-02-19 | Constellation Pharmaceuticals, Inc. | Dérivés d'indole utilisés en tant que modulateurs d'enzymes de modification du méthyle, compositions et utilisations associées |
MY186837A (en) | 2014-12-23 | 2021-08-25 | Novartis Ag | Triazolopyrimidine compounds and uses thereof |
WO2016130396A1 (fr) * | 2015-02-13 | 2016-08-18 | Constellation Pharmaceuticals, Inc. | Modulateurs d'enzymes de modification méthylique, compositions et utilisations associées |
US20180214519A1 (en) | 2015-07-24 | 2018-08-02 | Constellation Pharmaceuticals, Inc. | Combination therapies for modulation of histone methyl modifying enzymes |
AU2016302747A1 (en) | 2015-08-03 | 2018-02-22 | Constellation Pharmaceuticals, Inc. | EZH2 inhibitors and modulation of regulatory T-cell function |
AU2016312514A1 (en) | 2015-08-24 | 2018-03-15 | Epizyme, Inc. | Method for treating cancer |
TW201718598A (zh) | 2015-08-27 | 2017-06-01 | 美國禮來大藥廠 | Ezh2抑制劑 |
US10577350B2 (en) | 2015-08-28 | 2020-03-03 | Constellation Pharmaceuticals, Inc. | Crystalline forms of (R)-N-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide |
KR20180058829A (ko) | 2015-10-06 | 2018-06-01 | 에피자임, 인코포레이티드 | Ezh2 억제제로 수모세포종을 치료하는 방법 |
JP2019500623A (ja) | 2015-11-05 | 2019-01-10 | エピザイム,インコーポレイティド | ヒストンh3メチル化ステータスをモニターするためのフローサイトメトリー |
AU2017211331A1 (en) | 2016-01-29 | 2018-06-07 | Epizyme, Inc. | Combination therapy for treating cancer |
CN105669647B (zh) * | 2016-02-22 | 2018-05-04 | 上海皓元生物医药科技有限公司 | 一种组蛋白甲基化酶ezh2抑制剂中间体的合成方法 |
WO2017218953A1 (fr) | 2016-06-17 | 2017-12-21 | Epizyme, Inc. | Inhibiteurs d'ezh2 pour traiter le cancer |
WO2017219948A1 (fr) | 2016-06-20 | 2017-12-28 | Novartis Ag | Formes cristallines d'un composé de triazolopyrimidine |
CN109790166A (zh) * | 2016-06-20 | 2019-05-21 | 诺华股份有限公司 | 咪唑并吡啶化合物用于治疗癌症 |
ES2798424T3 (es) | 2016-06-20 | 2020-12-11 | Novartis Ag | Compuestos de triazolopiridina y usos de estos |
EP3529242A1 (fr) * | 2016-10-19 | 2019-08-28 | Constellation Pharmaceuticals, Inc. | Synthèse d'inhibiteurs d'ezh2 |
EP3548032A2 (fr) | 2016-12-02 | 2019-10-09 | Epizyme, Inc. | Combinaison thérapeutique pour traiter le cancer |
TW201831181A (zh) | 2017-01-19 | 2018-09-01 | 日商第一三共股份有限公司 | 用以用於治療htlv-1相關脊髓病之醫藥組成物 |
US10266542B2 (en) | 2017-03-15 | 2019-04-23 | Mirati Therapeutics, Inc. | EZH2 inhibitors |
US11642346B2 (en) | 2017-03-31 | 2023-05-09 | Epizyme, Inc. | Combination therapy for treating cancer |
WO2018231973A1 (fr) | 2017-06-13 | 2018-12-20 | Epizyme, Inc. | Inhibiteurs de ezh2 et leurs méthodes d'utilisation |
WO2019014191A1 (fr) | 2017-07-10 | 2019-01-17 | Constellation Pharmaceuticals, Inc. | Expression génique induite par un inhibiteur d'ezh2 |
US11459315B2 (en) | 2017-11-09 | 2022-10-04 | Constellation Pharmaceuticals, Inc. | Modulators of methyl modifying enzymes, compositions and uses thereof |
SG11202003477QA (en) | 2017-11-14 | 2020-05-28 | Pfizer | Ezh2 inhibitor combination therapies |
CN109879790B (zh) * | 2017-12-06 | 2022-09-20 | 华东师范大学 | 以吲哚或吲哚类似物为母核结构的酰胺类小分子有机化合物、用途及其制备方法 |
CN111757734A (zh) | 2017-12-28 | 2020-10-09 | 星座制药公司 | 通过组合疗法的ezh2抑制剂的药代动力学增强 |
JP7025556B2 (ja) | 2018-01-31 | 2022-02-24 | ミラティ セラピューティクス, インコーポレイテッド | Prc2阻害剤 |
CN110229157B (zh) * | 2018-03-06 | 2022-06-21 | 上海海和药物研究开发股份有限公司 | 嘧啶并五元芳香杂环类化合物、其制备方法及用途 |
CN110229151B (zh) * | 2018-03-06 | 2021-09-10 | 上海海和药物研究开发股份有限公司 | 吲嗪类化合物、其制备方法及用途 |
ES2942211T3 (es) | 2018-03-14 | 2023-05-30 | Biogen Ma Inc | Inhibidores de la O-glucoproteína-2-acetamido-2-desoxi-3-D-glucopiranosidasa |
EP3797108B1 (fr) | 2018-05-21 | 2022-07-20 | Constellation Pharmaceuticals, Inc. | Modulateurs de l'enzyme méthyl modifiant, compositions et leur utilisation. |
WO2020011607A1 (fr) | 2018-07-09 | 2020-01-16 | Fondation Asile Des Aveugles | Inhibition de sous-unités de prc2 permettant de traiter des troubles oculaires |
UY38376A (es) | 2018-09-19 | 2020-04-30 | Biogen Ma Inc | Inhibidores de o-glicoproteína-2-acetamido-2-desoxi-3-d-glucopiranosidasa |
UY38498A (es) | 2018-12-05 | 2020-07-31 | Biogen Ma Inc | Inhibidores de o-glucoproteina-2- acetamido-2-desoxi-3-d-glucopiranosidasa de morfolinilo , piperazinilo , oxazepanilo y diazepanilo |
WO2020139339A1 (fr) | 2018-12-27 | 2020-07-02 | Constellation Pharmaceuticals, Inc. | Inhibiteurs de la signalisation de l'ezh2 et du récepteur des androgènes en tant qu'outils pour le ciblage du cancer de la prostate |
EP3921316A1 (fr) | 2019-02-04 | 2021-12-15 | Biogen MA Inc. | Inhibiteurs d'éther o-glycoprotéine-2-acétamido-2-désoxy-3-d-glucopyranosidase bicycliques |
MA55203A (fr) | 2019-03-08 | 2022-01-12 | Biogen Ma Inc | Inhibiteurs d'azétidinyl 0-glyc0pr0téin-2-acétamid0-2-désoxy-3-d-gluc0pyran0sidase |
AU2020316072A1 (en) | 2019-07-24 | 2022-02-24 | Constellation Pharmaceuticals, Inc. | EZH2 inhibition in combination therapies for the treatment of cancers |
US20220251073A1 (en) * | 2019-07-24 | 2022-08-11 | Constellation Pharmaceuticals, Inc. | Crystalline forms of 7-chloro-2-(4-(3-methoxyazetidin-1-yl)cyclohexyl)-2,4-dimethyl-n-((6-methyl-4-(methylthio)-2-oxo-1,2-dihydropyridin-3-yl)methyl)benzo[d][1,3]dioxole-5-carboxamide |
CN114929709A (zh) | 2019-10-29 | 2022-08-19 | 比奥根Ma公司 | 螺环o-糖蛋白-2-乙酰胺基-2-脱氧-3-d-吡喃葡萄糖苷酶抑制剂 |
IL300365A (en) | 2020-08-03 | 2023-04-01 | Biogen Ma Inc | Crystal forms of O-glycoprotein-2-acetamido-2-deoxy-3-D-glucopyranosidase inhibitor |
CN112679505B (zh) * | 2020-12-25 | 2022-04-22 | 杭州澳赛诺生物科技有限公司 | 一种4-甲基-7H-吡咯并[2,3-d]嘧啶的合成方法 |
WO2022150962A1 (fr) | 2021-01-12 | 2022-07-21 | Westlake Pharmaceutical (Hangzhou) Co., Ltd. | Inhibiteurs de protéase, leur préparation et leurs utilisations |
WO2023111810A1 (fr) | 2021-12-14 | 2023-06-22 | Pfizer Inc. | Polythérapies et leurs utilisations pour le traitement du cancer |
TW202400140A (zh) | 2022-04-27 | 2024-01-01 | 日商第一三共股份有限公司 | 抗體-藥物結合物與ezh1及/或ezh2抑制劑之組合 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ603454A (en) * | 2010-05-07 | 2014-06-27 | Glaxosmithkline Llc | Indoles useful for treating cellular proliferation diseases such as cancer |
AU2012223448B2 (en) * | 2011-02-28 | 2017-03-16 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
JO3438B1 (ar) * | 2011-04-13 | 2019-10-20 | Epizyme Inc | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس |
WO2013120104A2 (fr) * | 2012-02-10 | 2013-08-15 | Constellation Pharmaceuticals | Modulateurs d'enzymes de modification par méthylation, leurs compositions et utilisations |
-
2014
- 2014-02-11 ME MEP-2017-141A patent/ME02730B/fr unknown
- 2014-02-11 EP EP14708987.4A patent/EP2953941B1/fr active Active
- 2014-02-11 RS RS20170680A patent/RS56207B1/sr unknown
- 2014-02-11 KR KR1020157024901A patent/KR102219441B1/ko active IP Right Grant
- 2014-02-11 MA MA38341A patent/MA38341B1/fr unknown
- 2014-02-11 CN CN201480019417.0A patent/CN105102446B/zh active Active
- 2014-02-11 SI SI201430274T patent/SI2953941T1/sl unknown
- 2014-02-11 TW TW103104340A patent/TWI629273B/zh active
- 2014-02-11 PL PL14708987T patent/PL2953941T3/pl unknown
- 2014-02-11 PE PE2015001728A patent/PE20160044A1/es active IP Right Grant
- 2014-02-11 WO PCT/US2014/015706 patent/WO2014124418A1/fr active Application Filing
- 2014-02-11 SG SG11201506077XA patent/SG11201506077XA/en unknown
-
2015
- 2015-07-16 IL IL239985A patent/IL239985B/en active IP Right Grant
- 2015-08-05 PH PH12015501720A patent/PH12015501720A1/en unknown
- 2015-08-11 CL CL2015002239A patent/CL2015002239A1/es unknown
- 2015-09-02 CR CR20150457A patent/CR20150457A/es unknown
-
2016
- 2016-06-08 HK HK16106614.5A patent/HK1218648A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
CR20150457A (es) | 2015-10-20 |
WO2014124418A1 (fr) | 2014-08-14 |
ME02730B (fr) | 2017-10-20 |
HK1218648A1 (zh) | 2017-03-03 |
EP2953941A1 (fr) | 2015-12-16 |
IL239985B (en) | 2018-11-29 |
CN105102446B (zh) | 2018-01-23 |
EP2953941B1 (fr) | 2017-04-05 |
KR20150119201A (ko) | 2015-10-23 |
MA38341B1 (fr) | 2018-11-30 |
PH12015501720B1 (en) | 2015-11-09 |
SI2953941T1 (sl) | 2017-08-31 |
CN105102446A (zh) | 2015-11-25 |
RS56207B1 (sr) | 2017-11-30 |
IL239985A0 (en) | 2015-09-24 |
PH12015501720A1 (en) | 2015-11-09 |
PL2953941T3 (pl) | 2017-11-30 |
PE20160044A1 (es) | 2016-02-11 |
KR102219441B1 (ko) | 2021-02-23 |
SG11201506077XA (en) | 2015-08-28 |
TW201443038A (zh) | 2014-11-16 |
TWI629273B (zh) | 2018-07-11 |
CL2015002239A1 (es) | 2016-02-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA38341A1 (fr) | Modulateurs d'enzymes de modification par méthylation, compositions et utilisations associées | |
PH12019502809A1 (en) | Substituted tricyclic compounds as fgfr inhibitors | |
MY172156A (en) | Modulators of methyl modifying enzymes, compositions and uses thereof | |
MA43187A (fr) | Formulations sous-cutanée d'anticorps anti-cd38 et leurs utilisations | |
MA47664B1 (fr) | Anticorps anti-c10orf54 et leurs utilisations | |
EA201790806A1 (ru) | Иммунорегулирующие средства | |
MA38686A1 (fr) | Anticorps anti-acide téichoïque de la paroi cellulaire et conjugués associés | |
MX2015017486A (es) | Inhibidores de indolamina 2,3-dioxigenasa (dio). | |
MA40534A (fr) | Inhibiteurs de mk2 et leurs utilisations | |
UA113543C2 (xx) | Сполуки та композиції для модулювання egfr активності | |
TR201900038T4 (tr) | GPR6'nın tetrahidropiridopirazin modülatörleri. | |
EA201170396A1 (ru) | 2-оксо-1,2-дигидрохинолиновые модуляторы иммунной функции | |
MX369388B (es) | Moduladores heterociclicos de sintesis lipidica. | |
AU2017317563A8 (en) | Detergent compositions comprising xanthan lyase variants I | |
TR201908247T4 (tr) | Sodyum glikoz birlikte taşıyıcı 1 inhibitörleri. | |
BR112013028449A2 (pt) | composições compreendendo partículas de hidrogel | |
MA44550A1 (fr) | Anticorps anti-acide téichoique de la paroi cellulaire et conjugués associés | |
MX2015010106A (es) | Moduladores de la proteina activadora de 5-lipoxigenasa. | |
AU2018253594A1 (en) | Dihydroxyphenyl neurotransmitter compounds, compositions and methods | |
MA39337B1 (fr) | Modulateurs de pyrazines de gpr6 | |
MA39000B1 (fr) | Compositions et méthodes permettant d'inhiber l'expression du gène alas1 | |
PH12016502133A1 (en) | Substituted tricycle compounds as fgfr inhibitors | |
TR201203085A2 (tr) | Sefetamet ve klavulanik asit içeren bileşimler. | |
EA202091923A1 (ru) | Замещенные трициклические соединения как ингибиторы fgfr | |
TR201002879U (tr) | Demirden mamül çok parçalı T bağlantı elemanı. |